文献速递免疫规划

菲律宾COVID-19疫苗接种后报告血液学不良事件:一项国家数据库研究

Hematologic adverse events reported after COVID-19 vaccination in the Philippines: A national database study.
PubMed 文献 · Vaccine · 2023-05-01

该研究基于菲律宾国家数据库,采用自身对照病例系列设计,分析了268例接种COVID-19疫苗后报告的血液学不良事件。总事件率为每10万剂0.0182例,淋巴腺病最常见(每10万剂0.011例),其次为贫血(0.0034)和血小板减少症(0.0017)。研究显示菲律宾使用的七种疫苗品牌接种后血液学不良事件发生率低。

要点

  • 总血液学不良事件率为每10万剂0.0182例。
  • 淋巴腺病最常见,率为每10万剂0.011例。
  • 多数事件(62.31%)发生在第一剂接种后。

核心结论

  • 研究显示菲律宾接种七种不同COVID-19疫苗品牌后血液学不良事件发生率低。

研究设计与样本

  • 自身对照病例系列研究,纳入菲律宾国家数据库中268例报告血液学不良事件的个体。

主要发现

  • 总事件率为每10万剂0.0182例;淋巴腺病最常见,率为每10万剂0.011例。
  • 贫血率为每10万剂0.0034例,血小板减少症率为每10万剂0.0017例,免疫性血小板减少症(ITP)率为每10万剂0.0007例。
  • 多数(62.31%)血液学不良事件发生在第一剂接种后;29.85%的个体接种了Comirnaty。
  • 截至写作时,132例(49.25%)完全康复,23.88%正在康复中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccination is the most important strategy in preventing COVID-19. Vaccine efficacy and safety have been established in clinical trials but real-world data are useful to determine occurrence of adverse events in a population with heterogeneous characteristics. Knowledge on the hematologic events associated with different COVID-19 vaccines would be beneficial for patients as well as hematologists who oversee the care of these patients. This study aimed to determine the rates and outcomes of hematologic adverse events after COVID-19 vaccination in the Philippines. In this self-controlled case series, there were 268 individuals reported to have hematologic adverse events. Most received Comirnaty at 29.85%. Majority (62.31%) reported hematologic adverse events following the first dose of the vaccine. The overall event rate was 0.0182 per 10,000 vaccine doses; and lymphadenopathy was the most common hematologic adverse effect with a rate of 0.011 per 10,000 vaccine doses, followed by anemia at 0.0034 per 10,000 vaccine doses and thrombocytopenia at 0.0017 per 10,000 vaccine doses. Autoimmune cytopenias were also reported with an event rate of 0.0007 per 10,000 vaccine doses for ITP. One-hundred thirty two (49.25%) were fully recovered and 23.88% were recovering from hematologic adverse events as of the time of writing. The study showed a low rate of hematologic adverse events post COVID-19 vaccination with the seven different vaccine brands administered in the Philippines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mesina FZ, Sapinoso FAD, De Castro JAV, et al. Hematologic adverse events reported after COVID-19 vaccination in the Philippines: A national database study. Vaccine. 2023. PMID: 37150619. doi:10.1016/j.vaccine.2023.04.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。